Sai Life Sciences Limited

BSE: 544306 NSE: SAILIFE
Sai Life Sciences Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24110TG1999PLC030970 Incorporated 25 January 1999 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: SAILIFE · BSE: 544306 Public Limited Company pharma Nifty 500
Data last updated
Market Cap
₹39,027 Cr
SAILIFE · NSE
Share Price
₹1,918.60
+4.45% today
Revenue
₹2,192 Cr
FY 2025-26 · +29.4% YoY
EBITDA
₹625 Cr
Margin 28.5%
Net Profit
₹356 Cr
FY 2025-26 · +107.4% YoY
P/E (TTM)
102.1x
P/B 14.5x
ROE
15.1%
ROCE 19.1%
Debt / Equity
0.14
Interest cover 8.9x

About Sai Life Sciences Limited

Data last updated:

Sai Life Sciences Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 25 January 1999 and has been in existence for over 27 years.

Sai Life Sciences is part of the Nifty 500 and BSE 500 indices. Its director Ranga Raju Kanumuri and family are #376 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24110TG1999PLC030970. Its GSTIN is 36AAECS6143F1ZF (Telangana). The company holds 6 GST registrations, of which 3 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 544306 and NSE: SAILIFE.

The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹21.25 Cr. It was formerly known as Sai Dru Syn Laboratories Limited and Sai Advantium Pharma Limited Definitions & Interpretation. It is led by directors including Krishnamraju Kanumuri (Managing Director) and Ranga Raju Kanumuri (Whole-Time Director).

Its last annual general meeting (AGM) was held on 17 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 7 Ikp Knowledge Park, Hyderabad, Telangana.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,192.49 Cr, a growth of 29.4% compared to the previous year. For the same year it recorded a net profit of ₹355.59 Cr (net margin 16.2%) and EBITDA of ₹624.77 Cr (EBITDA margin 28.5%). The net worth stands at ₹2,483.69 Cr (up 16.7% YoY). Total assets are valued at ₹2,804.46 Cr (up 12% YoY).

The company has about 2,995 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Sai Life Sciences. As per MCA filings, the company has open charges of ₹1,012.36 Cr and satisfied charges of ₹1,640.09 Cr on record. Court records list 15 cases involving the company, including 8 filed by the company and 7 filed against it; 4 cases are pending. The company has 42 deals on record (17 secondary share transfers, 13 funding rounds, 11 market trades), with disclosed funding of ₹454.6 Cr; the latest was in March 2026. Its 3 peer companies in the Pharma industry (Contract Research), with the same principal business activity (manufacture of chemicals and chemical products) are compared by revenue, 2 larger and 1 smaller; the largest is Amneal Pharmaceuticals Private Limited with revenue of ₹2,944.87 Cr. The company has 23 MSME Form 1 returns on record between 2019 and 2024, listing 4,922 overdue payments to 348 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sailife.com.

Company details

CIN L24110TG1999PLC030970
Registration Number 030970
Incorporation Date 25 January 1999
ROC Hyderabad
Listing Status Listed - Listed on NSE (SAILIFE); Listed on BSE (544306)
Company Status Active
Date of Last AGM 17 September 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Sai Life Sciences has undergone 4 name changes throughout its history. The current legal name is Sai Life Sciences Limited.

Company NameStatus
Sai Life Sciences LimitedCurrent
Sai Dru Syn Laboratories LimitedPrevious
Sai Advantium Pharma Limited Definitions & InterpretationPrevious
Sai Life Sciences Limited Definitions & InterpretationPrevious
Sai Advantium Pharma LimitedPrevious

CIN history

Sai Life Sciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24110TG1999PLC030970, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24110TG1999PLC030970Current
U24110TG1999PLC030970Previous
U24110AP1999PLC030970Previous
Key People
Krishnamraju Kanumuri Managing Director Ranga Raju Kanumuri Whole-Time Director Sivaramakrishnan Chittor Whole-Time Director

Recognitions & Rankings of Sai Life Sciences

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#352
Valuation
₹15,920 Cr
Stock market indices
Nifty 500 BSE 500

Contact details

Sai Life Sciences Limited's registered office is in Hyderabad, Telangana.

  • Social Media
  • Registered Address
    Plot No. Ds – 7 Ikp Knowledge Park Turkapally (V) Shameerpet Mandal Medchal – Malkajgiri Di, St, Hyderabad, Telangana, India – 500078
  • Industry
    Pharma, API Manufacturers, Pharma Contract R&D
Comprehensive company report
Sai Life Sciences Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Sai Life Sciences operates one associated brand: Sai Life Sciences. Each brand links to its own profile.

BrandDescriptionWebsite
Sai Life Sciences
Complex small molecules are discovered, developed, and manufactured for pharmaceuticals.sailife.com

Business activity

The main business activity of Sai Life Sciences is manufacturing. In detail, this covers manufacture of chemicals and chemical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing20Manufacture of chemicals and chemical products

To see the full business activity and turnover split of Sai Life Sciences Limited, buy the company report.

Financials of Sai Life Sciences Limited

FY 2025-26 filings available

Sai Life Sciences Limited reported revenue of ₹2,192.49 Cr (up 29.4% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,192 Cr
+29.4% YoY
EBITDA
₹625 Cr
+53.2% YoY
Profit After Tax
₹356 Cr
+107.4% YoY
Net Worth
₹2,484 Cr
+16.7% YoY
Total Assets
₹2,804 Cr
+12.0% YoY
Total Debt
₹288 Cr
-18.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1921,6951,4651,217870760726
Revenue growth+29.4%+15.7%+20.4%+40.0%+14.4%+4.7%-
EBITDA625408287169126167168
EBITDA margin+28.5%+24.1%+19.6%+13.9%+14.5%+22.0%+23.1%
Profit before tax46622810916.419.7081.91109
Net profit35617182.7810.21(5.08)61.0976.34
Net profit margin+16.2%+10.1%+5.7%+0.8%-0.6%+8.0%+10.5%
EPS (₹)16.488.1646.895.673.5535.0646.59
Balance sheet
Total assets2,8042,5041,9241,8411,8411,5481,145
Net worth2,4842,128975888879863794
Total debt288352928932751637304
Cash & bank11146415986.3413076.4198.25
Net working capital670960680681685595390
Cash flow
Cash from operations509314263219105(36.38)116
Cash from investing(395)(536)(191)(99.00)(102)(260)(262)
Cash from financing(124)301(95.30)(201)71.92296(4.07)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue659554602556537496580440
Revenue growth (YoY)+22.5%+11.7%+3.9%+26.5%+35.9%+77.5%--
Other income3.973.5415.818.3815.339.909.609.12
EBITDA186148177180146121158120
EBITDA margin+28.3%+26.7%+29.3%+32.3%+27.1%+24.4%+27.2%+27.2%
Depreciation48.1345.9445.3144.0839.7537.7237.4934.09
Interest10.947.647.839.709.3512.3610.8923.13
Profit before tax13197.9713913411280.7511971.65
Tax32.9624.6934.9933.8028.2020.3030.5317.80
Net profit98.3373.2810410083.8560.4588.2753.85
EPS (₹)4.583.424.874.713.932.904.142.84
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1531,6421,4191,157841751725
Revenue growth+31.1%+15.7%+22.6%+37.6%+11.9%+3.6%-
EBITDA593392288167125164170
EBITDA margin+27.6%+23.9%+20.3%+14.4%+14.9%+21.9%+23.4%
Profit before tax45623212932.6822.3687.59114
Net profit34817595.2224.614.3865.3180.13
Net profit margin+16.2%+10.7%+6.7%+2.1%+0.5%+8.7%+11.1%
EPS (₹)16.128.3253.9213.768.9336.6548.92
Balance sheet
Total assets2,7632,4781,8991,8021,7901,5451,137
Net worth2,5082,1671,011913891868794
Total debt223287868869751637304
Cash & bank10845815280.0212470.1092.97
Net working capital641947697684690584401
Cash flow
Cash from operations49533025122188.38(25.94)109
Cash from investing(393)(565)(190)(111)(94.63)(279)(259)
Cash from financing(109)314(84.63)(190)80.95304(1.40)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue647547594549527483567429
Revenue growth (YoY)+22.9%+13.2%+4.8%+28.1%+37.9%+82.6%--
Other income3.843.5416.048.4514.9310.019.829.45
Total expenses469407426378387370413317
EBITDA178140168171140113154111
EBITDA margin+27.5%+25.6%+28.3%+31.1%+26.6%+23.4%+27.1%+25.9%
Depreciation44.4042.1341.1640.6036.2134.3334.1031.07
Interest9.335.986.168.067.7010.709.1621.66
Profit before tax12895.3313713011177.9812067.91
Tax32.3023.9934.3232.8427.9219.6230.5316.85

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 11 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue659554602556537496580440
Revenue growth (YoY)+22.5%+11.7%+3.9%+26.5%+35.9%+77.5%--
Other income3.973.5415.818.3815.339.909.609.12
EBITDA186148177180146121158120
EBITDA margin+28.3%+26.7%+29.3%+32.3%+27.1%+24.4%+27.2%+27.2%
Depreciation48.1345.9445.3144.0839.7537.7237.4934.09
Interest10.947.647.839.709.3512.3610.8923.13
Profit before tax13197.9713913411280.7511971.65
Tax32.9624.6934.9933.8028.2020.3030.5317.80
Net profit98.3373.2810410083.8560.4588.2753.85
EPS (₹)4.583.424.874.713.932.904.142.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1921,6951,4651,217870760726
Revenue growth+29.4%+15.7%+20.4%+40.0%+14.4%+4.7%-
Other income49.1336.7829.0927.9728.1527.2917.84
Total expenses1,5681,2871,1781,048743593558
Employee cost683549495417301232214
EBITDA625408287169126167168
EBITDA margin+28.5%+24.1%+19.6%+13.9%+14.5%+22.0%+23.1%
Depreciation16713911999.4390.1679.5754.70
Interest40.8878.3487.5681.0254.4833.1421.70
Profit before tax46622810916.419.7081.91109
Tax11757.5726.436.423.4720.8232.76
Net profit35617182.7810.21(5.08)61.0976.34
Net profit margin+16.2%+10.1%+5.7%+0.8%-0.6%+8.0%+10.5%
EPS (₹)16.488.1646.895.673.5535.0646.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital21.1820.8418.0518.0117.9417.8216.38
Reserves & surplus2,4632,107957870861845777
Shareholders' funds (net worth)2,4842,128975888879863794
Minority interest0.000.000.000.000.000.000.00
Secured loans95.13129710699718603291
Unsecured loans19322421823333.8033.9812.42
Total debt288352928932751637304
Total liabilities2,8042,5041,9241,8411,8411,5481,145
Assets
Gross block2,6072,1161,6791,418937859810
Net block1,8151,4881,1801,037751701641
Capital work in progress27012410715141024690.96
Investments50.501.941.871.870.020.020.02
Inventories15111987.4414012776.3544.04
Sundry debtors374355256284243206270
Cash & bank balances11146415986.3413076.4198.25
Loans & advances728567443454444445201
Total current assets1,3641,505945964944804613
Total current liabilities693545265283259208222
Net working capital670960680681685595390
Total assets2,8042,5041,9241,8411,8411,5481,145
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash91.0511.9735.5311640.6241.40192
Net cash from operating activities509314263219105(36.38)116
Net cash from investing activities(395)(536)(191)(99.00)(102)(260)(262)
Net cash from financing activities(124)301(95.30)(201)71.92296(4.07)
Net change in cash(9.14)79.08(23.56)(80.25)75.15(0.78)(150)
Closing cash11146415986.3413076.4198.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+29.4%+15.7%+20.4%+40.0%+14.4%+4.7%-
EBITDA growth+53.2%+42.0%+70.0%+33.8%-24.6%-0.2%-
PBT growth+104.7%+108.5%+565.6%+69.2%-88.2%-24.9%-3.5%
Net income growth+107.4%+107.1%+710.8%+301.0%-108.3%-20.0%-
Revenue CAGR (3Y)+21.7%+24.9%+24.5%+18.8%+7.8%--
EBITDA CAGR (3Y)+54.7%+47.9%+19.7%+0.2%-10.4%--
Profitability & leverage
Net income margin+15.9%+10.0%+5.7%+0.8%+0.7%+8.0%+10.5%
Return on capital employed+19.1%+13.8%+10.5%+5.3%+3.1%+8.6%+12.1%
Return on net worth+15.1%+11.0%+8.9%+1.1%-0.6%+7.4%+10.1%
Debt / equity0.140.411.000.950.800.570.37
Long-term debt / equity0.070.200.490.430.310.200.10
Interest cover8.9329.1052.22116.64151.2137.7619.21
Efficiency & per share
Fixed asset turnover0.930.890.951.030.970.911.12
Inventory turnover16.2516.4312.919.148.5612.6216.40
Debtors turnover6.025.555.424.623.883.202.88
EPS (₹)16.488.1646.895.673.5535.0646.59
Dividend per share (₹)0.000.000.0038.3339.630.000.00
Book value per share (₹)117.28102.12551.96503.80500.21494.88484.03
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue647547594549527483567429
Revenue growth (YoY)+22.9%+13.2%+4.8%+28.1%+37.9%+82.6%--
Other income3.843.5416.048.4514.9310.019.829.45
Total expenses469407426378387370413317
EBITDA178140168171140113154111
EBITDA margin+27.5%+25.6%+28.3%+31.1%+26.6%+23.4%+27.1%+25.9%
Depreciation44.4042.1341.1640.6036.2134.3334.1031.07
Interest9.335.986.168.067.7010.709.1621.66
Profit before tax12895.3313713011177.9812067.91
Tax32.3023.9934.3232.8427.9219.6230.5316.85
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1531,6421,4191,157841751725
Revenue growth+31.1%+15.7%+22.6%+37.6%+11.9%+3.6%-
Other income49.1337.3429.3327.9628.1527.2917.84
Total expenses1,5601,2501,131991716587556
Employee cost618486431354263204202
EBITDA593392288167125164170
EBITDA margin+27.6%+23.9%+20.3%+14.4%+14.9%+21.9%+23.4%
Depreciation15212610787.7779.7071.7752.36
Interest34.0871.9481.1574.3850.9832.1121.26
Profit before tax45623212932.6822.3687.59114
Tax11558.2633.788.456.6722.2833.95
Net profit34817595.2224.614.3865.3180.13
Net profit margin+16.2%+10.7%+6.7%+2.1%+0.5%+8.7%+11.1%
EPS (₹)16.128.3253.9213.768.9336.6548.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital21.1820.8418.0518.0117.9417.8216.38
Reserves & surplus2,4872,147993895873850777
Shareholders' funds (net worth)2,5082,1671,011913891868794
Secured loans95.13129710699718603291
Unsecured loans12815915717033.8033.9812.42
Total debt223287868869751637304
Total liabilities2,7632,4781,8991,8021,7901,5451,137
Assets
Gross block2,4131,9441,5261,270884815784
Net block1,7051,3781,074923701659617
Capital work in progress27012410715134523678.97
Investments16311480.2780.2763.5663.3622.38
Inventories15011886.0713812673.3342.93
Sundry debtors370353259277237203269
Cash & bank balances10845815280.0212470.1092.97
Loans & advances725565454457457446204
Total current assets1,3521,495951952944792609
Total current liabilities711548254268253208208
Net working capital641947697684690584401
Total assets2,7632,4781,8991,8021,7901,5451,137
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash85.125.1729.2110934.3136.12188
Net cash from operating activities49533025122188.38(25.94)109
Net cash from investing activities(393)(565)(190)(111)(94.63)(279)(259)
Net cash from financing activities(109)314(84.63)(190)80.95304(1.40)
Net change in cash(6.52)79.95(24.04)(79.80)74.70(1.81)(152)
Closing cash10845815280.0212470.1092.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+31.1%+15.7%+22.6%+37.6%+11.9%+3.6%-
EBITDA growth+51.3%+36.2%+72.6%+33.6%-23.9%-3.3%-
PBT growth+96.9%+79.6%+294.8%+46.2%-74.5%-23.2%+1.6%
Net income growth+99.2%+83.6%+286.9%+461.9%-93.3%-18.5%-
Revenue CAGR (3Y)+23.0%+25.0%+23.6%+16.9%+6.6%--
EBITDA CAGR (3Y)+52.6%+46.5%+20.6%-0.6%-10.6%--
Profitability & leverage
Net income margin+15.9%+10.6%+6.7%+2.1%+1.9%+8.7%+11.1%
Return on capital employed+18.7%+13.9%+11.4%+6.0%+3.7%+8.9%+12.6%
Return on net worth+14.6%+10.9%+9.9%+2.7%+0.5%+7.9%+10.6%
Debt / equity0.110.360.900.900.790.570.37
Long-term debt / equity0.040.160.410.390.310.180.09
Interest cover7.7327.0144.8894.03112.8134.7518.09
Efficiency & per share
Fixed asset turnover0.990.951.021.080.990.941.14
Inventory turnover16.0616.0712.668.778.4412.9316.61
Debtors turnover5.965.375.294.503.833.182.88
EPS (₹)16.128.3253.9213.768.9336.6548.92
Dividend per share (₹)0.000.000.0038.3339.630.000.00
Book value per share (₹)118.42104.00572.28517.79507.50486.92484.05

To see the full year-wise statements and ratios of Sai Life Sciences Limited, buy the company report.

Board of directors of Sai Life Sciences Limited

Sai Life Sciences has 6 current directors and 28 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Krishnamraju Kanumuri
Also directs: Sai Life Pharma Private Limited, South India Research Institute Pvt Ltd
Managing Director01 Oct 201016 Years 1 MonthsCurrent
Ranga Raju Kanumuri
Also directs: JRV Properties LLP, Sai Quest Syn Private Limited, Ranmyt Trading Private Limited and 2 more
Whole-Time Director25 Jan 199927 Years 9 MonthsCurrent
Sivaramakrishnan ChittorWhole-Time Director28 Apr 20251 Years 6 MonthsCurrent
Dinesh Vinoobhai PatelDirector24 Mar 20251 Years 7 MonthsCurrent
Ramesh Ganesh Iyer
Also directs: Kotak Mahindra Bank Limited, Nocil Limited, Mahindra First Choice Wheels Limited and 3 more
Director21 May 20242 Years 5 MonthsCurrent
Suchita Sharma
Also directs: Roppen Transportation Services Private Limited
Director10 Jun 20242 Years 5 MonthsCurrent
View all directors

Peer comparison

Sai Life Sciences Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (manufacture of chemicals and chemical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Amneal Pharmaceuticals Private Limited₹2,944.87 Cr (FY 2025)6.0%Ahmedabad, Gujarat, India
Sai Life Sciences Limitedthis company₹2,192.49 Cr (FY 2026)₹355.59 Cr16.2%29.4%Hyderabad, Telangana, India
Anthem Biosciences Limited₹1,930.28 Cr (FY 2025)30.0%Bangalore, Karnataka, India
Onesource Specialty Pharma Limited₹1,462.33 Cr (FY 2025)730.0%Thane, Maharashtra, India

To see the full peer comparison of Sai Life Sciences Limited, buy the company report.

Charges & borrowings

Open charges
₹1,012.36 Cr
Satisfied charges
₹1,640.09 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹1,012.36 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
16 Jul 2026101357702Sbicap Trustee Company Limited₹100 CrOpen
06 Oct 2023100804230Sbicap Trustee Company Limited₹768.6 CrOpen
06 Oct 2023100817131Sbicap Trustee Company Limited₹25 CrOpen
06 Oct 2023100817141Sbicap Trustee Company Limited₹18.76 CrOpen
06 Oct 2023100817312Sbicap Trustee Company Limited₹100 CrOpen

To see the full charge records of Sai Life Sciences Limited, buy the company report.

Total charge records: 39 View all charges

Deals & funding

Sai Life Sciences Limited has 42 deals on record (17 secondary share transfers, 13 funding rounds, 11 market trades), with disclosed funding of ₹454.6 Cr; the latest was in March 2026.

Total deals
42
Secondary share transfers
17
Funding rounds
13
Market trades
11
IPO
1
Disclosed funding
₹454.6 Cr

Deals on record (5 of 42)

WhenDealAmountParties
Jun 2025Market trade₹1,504.75 CrBuyer: Nippon India Mutual Fund, Axis Max Life Insurance Limited , Aditya Birla Sun Life Mutual Fund
Seller: Tpg Asia Vii Sf Pte Ltd
Jun 2025Market trade₹1,492.25 CrBuyer: Nippon India Mutual Fund, Aditya Birla Sun Life Mutual Fund, Invesco Mutual Fund
Seller: Tpg Asia Vii Sf Pte Ltd
Dec 2024Market trade₹194.94 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP , an individual
Dec 2024Market trade₹114.36 CrBuyer: Irage Broking Services LLP
Seller: Irage Broking Services LLP
Dec 2024Market trade₹335.41 CrBuyer: Aakraya Research LLP , Nippon India Mutual Fund, NK Securities Research Private Limited
Seller: Aakraya Research LLP , Irage Broking Services LLP , NK Securities Research Private Limited

To see the full deal history of Sai Life Sciences Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Sai Life Sciences Limited has 23 MSME Form 1 returns on record between 2019 and 2024, listing 4,922 overdue payments to 348 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 348)

SupplierAmount dueDue sinceReported on
an individual supplier
an individual supplier
Zenith Imports and Exports
Labx Systia
Azole Chem Private Limited

To see the full MSME payment records of Sai Life Sciences Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

GST

Sai Life Sciences has 6 GST registrations: 3 active and 3 cancelled or inactive.

Total GSTINs
6
Active
3
Cancelled / inactive
3
GSTINStateStatusRegistered on
36AAECS6143F1ZFTelanganaActive01 Jul 2017
36AAECS6143F2ZETelanganaActive15 Mar 2018
29AAECS6143F1ZAKarnatakaActive01 Jul 2017

To see the full GST registrations and return filing status of Sai Life Sciences Limited, buy the company report.

Recent activity

Sai Life Sciences Limited has 34 board changes on record since 1999: 6 appointments and 28 cessations. The latest: Dinesh V Patel ceased to be Additional Director on 15 Jun 2025.

AGM
Sai Life Sciences Limited last Annual general meeting of members was held on 17 Sep 2026 as per latest MCA records.
Charges
A charge registered on 13 Mar 2026 via Charge ID 101268280 with Axis Bank Limited was fully satisfied on 18 Aug 2026.
Charges
A charge with Sbicap Trustee Company Limited amounted to Rs. 100.00 Cr with Charge ID 101357702 was registered on 16 Jul 2026.
Filing
Sai Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Charges
A charge with Axis Bank Limited amounted to Rs. 50.00 Cr with Charge ID 101268280 was registered on 13 Mar 2026.
Ceased
Dinesh V Patel ceased to be Additional Director.
Appointed
Sivaramakrishnan Chittor was appointed as Whole-Time Director.
Charges
A charge registered on 06 Oct 2023 via Charge ID 100817152 with Sbicap Trustee Company Limited was fully satisfied on 26 Mar 2025.
Charges
A charge registered on 06 Oct 2023 via Charge ID 100817174 with Sbicap Trustee Company Limited was fully satisfied on 26 Mar 2025.
Charges
A charge registered on 06 Oct 2023 via Charge ID 100817302 with Sbicap Trustee Company Limited was fully satisfied on 26 Mar 2025.
Charges
A charge registered on 06 Oct 2023 via Charge ID 100817497 with Sbicap Trustee Company Limited was fully satisfied on 26 Mar 2025.
Charges
A charge registered on 06 Oct 2023 via Charge ID 100819140 with Sbicap Trustee Company Limited was fully satisfied on 26 Mar 2025.

132 earlier events are in the company report.

News

Sai Life: Co's Medium-term Guidance Is 15-18% Revenue CAGR With 28-30% Margin
11 Nov 2026 · Exchange Update

Frequently asked questions

Sai Life Sciences is an active public limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 25 January 1999 (27+ years old) and is registered under CIN L24110TG1999PLC030970. Listed on BSE: 544306 and NSE: SAILIFE.

Sai Life Sciences reported revenue of ₹2,192.49 Cr for FY 2025-26 (up 29.4% YoY) based on consolidated financials.

Sai Life Sciences has 6 current directors:

The latest financial statements of Sai Life Sciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 17 September 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Sai Life Sciences is 36AAECS6143F1ZF, registered in Telangana. The company has 6 GST registrations in all, of which 3 are active and 3 are cancelled or inactive. Other active GSTINs include 36AAECS6143F2ZE (Telangana), 29AAECS6143F1ZA (Karnataka).

The CIN (Corporate Identification Number) of Sai Life Sciences is L24110TG1999PLC030970. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Sai Life Sciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 544306) and NSE (symbol: SAILIFE).

Sai Life Sciences has 15 court cases on record: 8 filed by the company and 7 filed against it. 4 are pending. Most are in the district courts.

Sai Life Sciences was incorporated on 25 January 1999, making it 27+ years old. It is registered with the Registrar of Companies, Hyderabad.

Sai Life Sciences has 42 deals on record (17 secondary share transfers, 13 funding rounds, 11 market trades), with disclosed funding of ₹454.6 Cr; the latest was in March 2026.

The peers of Sai Life Sciences by revenue are Amneal Pharmaceuticals Private Limited, Anthem Biosciences Limited, Onesource Specialty Pharma Limited, all in the Pharma industry (Contract Research), with the same principal business activity (manufacture of chemicals and chemical products).

Dinesh V Patel ceased to be Additional Director on 15 Jun 2025. Sivaramakrishnan Chittor was appointed as Whole-Time Director on 28 Apr 2025. Dinesh Vinoobhai Patel was appointed as Director on 24 Mar 2025. Sai Life Sciences has 34 board changes on record in total.